Page last updated: 2024-12-11
sitosterol palmitate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9852570 |
SCHEMBL ID | 4739259 |
MeSH ID | M0456668 |
Synonyms (25)
Synonym |
---|
beta-sitosteryl palmitate |
16:0 sitosteryl ester |
stigmast-5-en-3beta-yl hexadecanoate |
LMST01020047 |
SCHEMBL4739259 |
sitosteryl palmitate |
2308-85-2 |
sitosteryl palmitate, (+)- |
sitosterol palmitate |
stigmast-5-en-3-ol, 3-hexadecanoate, (3.beta.)- |
LEB596GYDL , |
.beta.-rosasterol palmitate |
stigmast-5-en-3.beta.-ol, palmitate |
.beta.-sitosteryl palmitate |
beta-rosasterol palmitate |
stigmast-5-en-3beta-ol, palmitate |
unii-leb596gydl |
stigmast-5-en-3-ol, 3-hexadecanoate, (3beta)- |
AKOS032962160 |
Q27896637 |
FS-9628 |
sitosterol palmitate;-sitosterol hexadecanoate; -sitosteryl palmitate |
DTXSID601315058 |
[(3s,8s,9s,10r,13r,14s,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hexadecanoate |
caffeoyl pentose |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.63
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |